Native name 大塚製薬株式会社 Number of employees 25,330 | Founded 1964 | |
 | ||
Romanized name Ōtsuka Seiyaku Kabushiki-gaisha Traded as TYO: 4578TOPIX 100 Component Parent Otsuka Holdings Co. Ltd CEO Kazumichi Kobayashi (23 Jan 2007–) CFO Edward Stelmakh (CPA, CMA) Subsidiaries Avanir Pharmaceuticals Inc, Pharmavite VPs John A. Bardi (M.s., Government Affairs, Advocacy, Digital Medicines Business Development) | ||
How to pronounce otsuka pharmaceutical
Otsuka Pharmaceutical Co., Ltd. (大塚製薬株式会社, Ōtsuka Seiyaku Kabushiki-gaisha) (TYO: 4578), abbreviated OPC, is a pharmaceutical company headquartered in Tokyo, Osaka and Naruto, Japan. The company was established August 10, 1964. As of 2012, OPC employed 40,000 people worldwide. The company focuses on pharmaceuticals related to nutrition (or "nutraceuticals"). The company is also known for the popular sports drink Pocari Sweat and the best-selling energy drink Oronamin C. Otsuka Pharmaceutical also developed Abilify (aripiprazole), an approved drug treatment for schizophrenia and bipolar disorder, which they claim has a better side effect profile compared with other antipsychotic drugs. As of 2013, annual sales of Abilify were over $8 billion a year, making it the highest grossing drug worldwide as of late 2013.
Contents
- How to pronounce otsuka pharmaceutical
- Hula otsuka pharmaceutical co ltd
- Company history
- Products
- References
OPC's parent company Otsuka Holdings Co. Ltd. joined the Tokyo Stock Exchange through an initial public offering (IPO) on December 15, 2010, at which time Otsuka Holdings was Japan's No.2 drug maker by sales after industry leader Takeda Pharmaceutical Company. The IPO debuted at $2.4 billion, making it the largest for a pharmaceutical company up to that time.
Hula otsuka pharmaceutical co ltd
Company history
In early 2012, Otsuka announced it would focus its "future operations on CNS disorders and oncology". This decision necessitated a revision in the terms of an agreement with UCB to end collaboration on immunology products while continuing collaboration in the CNS area.
In September 2013, Otsuka Holdings announced it had agreed to acquire Astex Pharmaceuticals for close to $900 million.
In December 2014, Otsuka Holdings struck a deal to buy Avanir Pharmaceuticals for $3.54 billion.
In March 2017, the company agreed to acquire Neurovance, inc for $250 million, gaining the firm’s Phase III-ready ADHD drug centanafadine (previously EB-1020). Otsuka's subsidiary Otsuka America will pay $100 million upfront for Neurovance, plus up-to $150 million in development and approval milestones. As a result of the transaction, Neurovance will operate as an indirect, wholly owned subsidiary.